Novartis AG's decision to disband its cell and gene therapy unit – the business responsible for developing one of the most advanced CAR-T therapies in the industry – has raised questions about the Swiss pharma’s outlook for an area of oncology research that has been thought to be groundbreaking.
It was only four years ago that Novartis in-licensed the CAR-T (chimeric antigen receptor T-cell) technology from the University of...